A potent class of GPR40 full agonists engages the enteroinsular axis to promote glucose control in rodents.
about
A novel antidiabetic drug, fasiglifam/TAK-875, acts as an ago-allosteric modulator of FFAR1Pharmacology and physiology of gastrointestinal enteroendocrine cellsPotential roles of GPR120 and its agonists in the management of diabetesPhysiology of proglucagon peptides: role of glucagon and GLP-1 in health and diseaseA bitter pill for type 2 diabetes? The activation of bitter taste receptor TAS2R38 can stimulate GLP-1 release from enteroendocrine L-cellsAlteration of the glucagon axis in GPR120 (FFAR4) knockout mice: a role for GPR120 in glucagon secretion.Treatment with CNX-011-67, a novel GPR40 agonist, delays onset and progression of diabetes and improves beta cell preservation and function in male ZDF ratsGPR40 (FFAR1) - Combined Gs and Gq signaling in vitro is associated with robust incretin secretagogue action ex vivo and in vivoDifferential Gene Expression in GPR40-Overexpressing Pancreatic β-cells Treated with Linoleic Acid.Free fatty acid receptors: structural models and elucidation of ligand binding interactions.The pharmacology of TUG-891, a potent and selective agonist of the free fatty acid receptor 4 (FFA4/GPR120), demonstrates both potential opportunity and possible challenges to therapeutic agonismLongitudinal profiling of the tissue-specific expression of genes related with insulin sensitivity in dairy cows during lactation focusing on different fat depots.Minireview: The effects of species ortholog and SNP variation on receptors for free fatty acids.Are GPCRs still a source of new targets?Characterizing pharmacological ligands to study the long-chain fatty acid receptors GPR40/FFA1 and GPR120/FFA4.Treatment of type 2 diabetes by free Fatty Acid receptor agonists.GPR40 agonists for the treatment of type 2 diabetes: life after 'TAKing' a hit.Fatty acid and mineral receptors as drug targets for gastrointestinal disorders.Potential mechanism of enhanced postprandial glucagon-like peptide-1 release following treatment with a diacylglycerol acyltransferase 1 inhibitor.The Role and Future of FFA1 as a Therapeutic Target.Free fatty acid receptor agonists for the treatment of type 2 diabetes: drugs in preclinical to phase II clinical development.PPARγ signaling and emerging opportunities for improved therapeutics.Targeting orphan G protein-coupled receptors for the treatment of diabetes and its complications: C-peptide and GPR146.GPR40 reduces food intake and body weight through GLP-1.Polymorphic Variation in FFA Receptors: Functions and Consequences.Key Questions for Translation of FFA Receptors: From Pharmacology to Medicines.Gut Hormone Regulation and Secretion via FFA1 and FFA4.In vitro and mouse in vivo characterization of the potent free fatty acid 1 receptor agonist TUG-469.Free Fatty Acid Receptor 1 (FFAR1) as an Emerging Therapeutic Target for Type 2 Diabetes Mellitus: Recent Progress and Prevailing Challenges.Application of GPCR Structures for Modelling of Free Fatty Acid Receptors.Discovery and Optimization of Potent GPR40 Full Agonists Containing Tricyclic Spirocycles.Improving the Pharmacokinetics of GPR40/FFA1 Full AgonistsVirtual Systems Pharmacology (ViSP) software for simulation from mechanistic systems-level models.Vascular, but not luminal, activation of FFAR1 (GPR40) stimulates GLP-1 secretion from isolated perfused rat small intestine.GPR40 partial agonists and AgoPAMs: Differentiating effects on glucose and hormonal secretions in the rodent.The current state of GPCR-based drug discovery to treat metabolic disease.G-protein-coupled receptors for free fatty acids: nutritional and therapeutic targets.Structural basis for GPR40 allosteric agonism and incretin stimulation.Activity of dietary fatty acids on FFA1 and FFA4 and characterisation of pinolenic acid as a dual FFA1/FFA4 agonist with potential effect against metabolic diseasesTargeting the intestinal L-cell for obesity and type 2 diabetes treatment
P2860
Q24338456-D4D2CA5A-6A28-4C53-AB13-9066AF205835Q26799380-81467BB1-981D-407C-8A8C-1B809EFC03B6Q26827101-186E62B7-1B10-47F0-A3D9-F10ACD3797BCQ27027920-843A6835-B0D5-4BE1-B2BA-923BF21304AFQ28829204-BCFA2E83-B383-43AD-888A-8C490E14F1DDQ34076033-0FCCEEF4-3280-41E9-B30E-328870DDED8CQ34732874-7D768F00-CE08-4EF1-94E1-E2CAA710392CQ35040481-3B4591B2-4901-458E-933E-2943B1123866Q35127471-BB6E2B72-7424-4F38-9449-080B6BB55E10Q35766268-4DE55D73-0F0D-44E0-9E14-79C69F0C1523Q37252074-C981723B-4FE1-4B80-96E4-3D2D6A54ACB2Q37500233-78524643-82D8-477D-ADEA-DBA33F603CA8Q38107811-764A1118-ED56-4C68-90E3-A2FC57537625Q38129012-D7C5F432-A77B-47A0-B442-22E54A3233C8Q38240702-3314CCD9-FE77-4288-A445-E364DF357286Q38249182-01509542-163D-43B8-B831-98AB628392CAQ38325894-79F4662F-90EE-48B4-AC75-3A3011D42B54Q38756670-2AD6AD59-1667-4968-B234-68774EEA0649Q38761874-9BBA27DB-258D-4CE4-AD3C-8599777B73D9Q38799812-0F2031DA-ED52-4635-8851-05942B7F42C3Q38832716-74612FA4-6DF7-4651-9E33-CD81DA3BC027Q38856983-21EFBD41-6632-4905-91D3-E29781BF4D7CQ38866310-523B9321-F4B1-4A2D-B797-92D6458A3303Q38908392-973B51BA-C585-4618-B2A4-C9F655111165Q39013784-F6551AB7-0299-4360-830A-7201DF95FB66Q39016250-A86E8E67-57C9-4242-A0A1-D06000970009Q39016255-51190C31-B9CC-443F-A9D5-EDF1A13DBD6BQ39124913-9F68B9CF-0D2D-4C41-82A5-AA27B8410AD2Q39192856-3A5F3875-6A3D-4F70-887D-08172FD46617Q39273205-5ED71F10-057C-4979-A460-FBB5670CB247Q39779287-DE3CDBB5-FE62-47FC-8176-0E56EB79E6E4Q39782891-00BFEE45-BDFF-4878-9D4B-465F2D10F6A0Q41788959-6DAC65C2-0387-445C-95F1-E421628A2793Q42141283-8589AC24-AAC8-4666-88CD-AD023067EE4CQ47105671-E24711A6-EDF0-4520-B0C1-BF75C5EF7242Q47696468-A4CB0CE6-DC89-44E5-8B30-EED7E6028F99Q51762114-452ACA81-EA2A-46E7-85A1-C7D407C5AC12Q52309488-AE0D7229-AE78-49C1-8503-FB90E163628BQ57907251-F3FD11F9-6B73-4638-A273-512CD4B3939FQ58447645-7D697C56-4128-48E6-A6C4-2D282334518B
P2860
A potent class of GPR40 full agonists engages the enteroinsular axis to promote glucose control in rodents.
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
A potent class of GPR40 full a ...... te glucose control in rodents.
@ast
A potent class of GPR40 full a ...... te glucose control in rodents.
@en
A potent class of GPR40 full a ...... te glucose control in rodents.
@nl
type
label
A potent class of GPR40 full a ...... te glucose control in rodents.
@ast
A potent class of GPR40 full a ...... te glucose control in rodents.
@en
A potent class of GPR40 full a ...... te glucose control in rodents.
@nl
prefLabel
A potent class of GPR40 full a ...... te glucose control in rodents.
@ast
A potent class of GPR40 full a ...... te glucose control in rodents.
@en
A potent class of GPR40 full a ...... te glucose control in rodents.
@nl
P2093
P2860
P1433
P1476
A potent class of GPR40 full a ...... te glucose control in rodents.
@en
P2093
Daniel C-H Lin
Gayathri Swaminath
Jane Zhang
Jonathan B Houze
Kathy Nguyen
Marc Vimolratana
P2860
P304
P356
10.1371/JOURNAL.PONE.0046300
P407
P577
2012-10-09T00:00:00Z